SAN DIEGO, Feb. 16, 2021 /PRNewswire/ -- Evofem Biosciences,
Inc., (NASDAQ: EVFM) today announced the launch of "Get Phexxi", a
national direct-to-consumer (DTC) campaign aimed at broadening
awareness of its non-hormonal, use-it-only-when-you-need-it birth
control method, Phexxi® (lactic acid, citric acid and potassium
bitartrate).
Approved by the U.S. Food and Drug Administration (FDA) in
May 2020, Phexxi is an
innovative non-hormonal contraceptive method created for women.
With 21 million women in the U.S. at risk for pregnancy who are NOT
using hormonal contraception1, the time is right for the
"Get Phexxi" campaign to educate women about this innovative birth
control option.
The campaign highlights some of the struggles women face when
choosing among the many available methods of contraception, whether
it's the lack of control with condoms, constant daily use of the
pill, or abstinence required for cycle tracking. The women featured
in the commercial represent the real-life drawbacks that Phexxi may
help eliminate as a hormone-free, on-demand birth control
method.
"Get Phexxi" will launch nationally, airing the brand's
first-ever commercial across broadcast, connected, and streaming
television networks. The campaign will extend broadly to reach
women across numerous other touch points through a highly targeted
and multipronged digital and social media plan, as well as reach
consumers at the point of care. The Valentine's Day launch timing
is a nod to women who are looking for ways to add to their
self-care and self-love toolkit.
"In our extensive market research, we heard repeatedly from
women that they are frustrated with the birth control methods
previously available to them, which left them fed up with side
effects and lack of control," said Evofem Biosciences' CEO,
Saundra Pelletier. "With half of all
pregnancies in the U.S. unplanned, there is a clear need for
additional, innovative birth control methods. This marketing
campaign is designed to bring awareness to how Phexxi can fill the
unmet needs of millions of women."
To view the "Get Phexxi" commercial on demand, visit YouTube.
Join the conversation on social media, including Instagram
(@Phexxi and @EvofemBiosciences), Facebook (@Phexxi and
@Evofem) and Twitter (@Evofem).
About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage
biopharmaceutical company committed to developing and
commercializing innovative products to address unmet needs in
women's sexual and reproductive health, including hormone-free,
woman-controlled contraception and protection from certain sexually
transmitted infections (STIs). The Company's
first commercial product, Phexxi®, is the first and
only hormone-free, prescription vaginal gel approved in
the United States for the
prevention of pregnancy. The Company's lead product candidate,
EVO100, is being evaluated for the prevention of urogenital
Chlamydia trachomatis and Neisseria gonorrhoeae
infection in women in the ongoing Phase 3 clinical trial,
'EVOGUARD.' For more information, please visit www.evofem.com.
Phexxi® is a registered trademark of Evofem Biosciences,
Inc.
About PHEXXI®
Phexxi® is an on-demand
method of birth control used to prevent pregnancy.
Phexxi® is not effective when used after sex.
IMPORTANT SAFETY INFORMATION
- If you have had a history of repeated urinary tract infections
or other urinary tract problems, avoid Phexxi®.
- The most common side effects were vaginal burning, vaginal
itching, vaginal yeast infection, urinary tract infection, vaginal
area discomfort, bacterial vaginosis, vaginal discharge, genital
discomfort (including male partners), and pain while
urinating.
- Phexxi® does not protect against any sexually transmitted
infections, including HIV.
- Contact your healthcare provider if you are experiencing severe
genital irritation or discomfort or urinary tract symptoms.
For more information about Phexxi®, talk to your healthcare
provider and see full Product Information.
Please report side effects by contacting Evofem Biosciences®
toll-free at 1-833-EVFMBIO or contact FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.
Forward Looking
Statements
This press release includes "forward-looking
statements," within the meaning of the safe harbor for
forward-looking statements provided by Section 21E of the
Securities Exchange Act of 1934, as amended, and the Private
Securities Litigation Reform Act of 1995 including, without
limitation, statements related to the expected impact of the
"Get Phexxi" campaign on consumer behavior, brand uptake, and
future growth of Phexxi and the
Company. Various factors could cause actual
results to differ materially from those discussed or implied in the
forward-looking statements, and you are cautioned not to place
undue reliance on these forward-looking statements, which are
current only as of the date of this press release. Each of these
forward- looking statements involves risks and uncertainties.
Important factors that could cause actual
results to differ materially from those discussed or implied in the forward-looking statements, or
that could impair the value of Evofem Biosciences' assets and business, are disclosed in Evofem's
SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2019 filed
with the SEC on March 12, 2020, its
Current Report on Form 8-K filed with the SEC on June 2, 2020, and its Quarterly Report on Form
10-Q for the quarter ended September 30,
2020 filed
with the SEC on November 9, 2020. All forward-looking statements are expressly qualified in their
entirety by such factors. Evofem does not undertake any duty to
update any forward-looking statement except as required
by law.
References
1. Daniels K, Abma JC. Current
contraceptive status among women aged 15-49: United States, 2015- 2017. NCHS Data Brief.
2018; 327: 1-14.
Investor Relations Contact
Amy
Raskopf
Evofem Biosciences, Inc. araskopf@evofem.com Mobile: (917)
673-5775
Media Contact
Bonnie
Efird
Capwell Communications, Inc. bonnie@capwellcomm.com Mobile: (704)
806-5119
View original content to download
multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-launches-us-direct-to-consumer-campaign-to-accelerate-awareness-of-phexxi-a-non-hormonal-birth-control-option-for-women-301228092.html
SOURCE Evofem Biosciences, Inc.